"There are now 404 patients undertaking the trial instead of the previously scheduled 360 patients .... no cost to participants and previously publicised results obviously contributed to the increase in demand for inclusion perhaps ?"
Not sure why you find these enrolment figures worthy of remark.
An extra 44 enrolments in the context of the millions of people suffering from degenerative disc disease in the US (see @stockrock's subsequent post this morning) is statistically irrelevant.
One really wouldn't have been surprised to see enrolments in the thousands, if the circumstances warranted it.
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment, page-5
-
- There are more pages in this discussion • 268 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |